| Literature DB >> 10745268 |
A L Pecora1, P Stiff, A Jennis, S Goldberg, R Rosenbluth, P Price, K L Goltry, J Douville, R D Armstrong, A K Smith, R A Preti.
Abstract
Delayed engraftment, graft failure, and adverse transplant-related events have been observed in unrelated umbilical cord blood (UCB) recipients, particularly in those receiving a low leukocyte cell dose and in CML patients. We report the outcomes of two older adult patients with high risk CML who received a low leukocyte cell dose of unmanipulated UCB cells supplemented with ex vivo expanded (AastromReplicell System) UCB cells. Each engrafted promptly and neither patient experienced GVHD or life-threatening infection. Both remain engrafted with cells exclusively of donor origin and are in cytogenetic remission at 19 and 8 months follow-up. Ex vivo expanded UCB cells appear to facilitate hematopoietic recovery and therefore may increase the number of CML patients eligible for unrelated UCB transplant.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10745268 DOI: 10.1038/sj.bmt.1702222
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483